Intermittent fasting modulates the intestinal microbiota and improves obesity and host energy metabolism

Hu, Xiangwei; Xia, Kai; Dai, Minhui; Han, Xiaofeng; Yuan, Peng; Liu, Jia; Liu, Shiwei; Jia, Fuhuai; Chen, Jiayu; Jiang, Fangfang; Yu, Jieyao; Yang, Huanming; Wang, Jian; Xu, Xun; Jin, Xin; Kristiansen, Karsten; Xiao, Liang; Chen, Wei; Han, Mo; Duan, Shenglin

doi:10.1038/s41522-023-00386-4

Cited by 19 publications

(7 citation statements)

References 49 publications

(58 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to that, the anticancer medications covered in the existing literature are all IV chemotherapies, while, in this review, we present orally administered targeted agents that rely on multiple factors for their bioavailability. These factors could include administration with respect to food (e.g., venetoclax [ 60 ]) and the gut microbiota that is altered by IF [ 20 , 74 ].…”

Section: Discussion and Future Directionsmentioning

confidence: 99%

The Safety of Novel Therapies in Chronic Lymphocytic Leukemia in the Era of Intermittent Fasting: A Pharmacology-Based Review

Benkhadra,

Fituri,

Aboukhalaf

et al. 2024

Cancers

View full text Add to dashboard Cite

Intermittent fasting (IF) has recently gained popularity due to its emerging benefits in reducing weight and improving metabolic health. Concurrently, novel agents (NAs) like venetoclax and Bruton tyrosine kinase inhibitors (BTKIs) have revolutionized the treatment of chronic lymphocytic leukemia (CLL). Unfortunately, it is unclear whether the associated risks of tumor lysis syndrome (TLS) and gastrointestinal bleeding (GIB) are increased in IF practitioners receiving NAs. This review explored the literature available on the permissibility of IF in CLL patients undergoing treatment with first-line NAs (FLNAs). Literature was scoped to identify IF patterns and the available data on TLS and GIB risks associated with food and fluid intake in CLL patients receiving FLNAs. Although current evidence is insufficient to recommend IF in this population, it may be possible for patients on venetoclax to conservatively practice fluid-liberal IF, provided that adequate hydration and the consistent administration of food are achieved. In contrast, considering the significant risk of TLS and the pharmacokinetics of venetoclax, patients should be discouraged from practicing fluid-restricted IF, especially during the ramp-up phase. Moreover, patients on BTKIs ought to refrain from IF due to the possible risk of GIB until further data are available. Further research is needed to provide conclusive recommendations.

show abstract

Section: Discussion and Future Directionsmentioning

confidence: 99%

The Safety of Novel Therapies in Chronic Lymphocytic Leukemia in the Era of Intermittent Fasting: A Pharmacology-Based Review

Benkhadra,

Fituri,

Aboukhalaf

et al. 2024

Cancers

View full text Add to dashboard Cite

show abstract

“…The results published by Hu et al have shown that intermittent fasting generates changes in the microbiota by increasing the number of bacteroides and parabacteroides, which are known to be involved in beneficial effects on health [ 29 ]. In addition, enrichment of GABA-producing P. distasonis and B. thetaiotaomicron was observed.…”

Section: Discussionmentioning

confidence: 99%

Intermittent Fasting and Reduction of Inflammatory Response in a Patient with Ulcerative Colitis

Roco-Videla,

Villota-Arcos,

Pino-Astorga

et al. 2023

Medicina

View full text Add to dashboard Cite

Ulcerative colitis is an inflammatory disease that affects the colon, generating a crisis period associated with diarrhea and ulcerations. Stress plays a pivotal role in modulating the inflammatory response and aggravating progression. Different studies have shown that fasting reduces inflammation markers, and intermittent fasting decreases inflammatory markers such as IL-2, IL-6, and RCP. Goal: To evaluate the impact of intermittent fasting on a patient diagnosed with ulcerative colitis. A female patient underwent intermittent fasting (10/14) for eight weeks. Clinical tests were performed for blood count, RCP, biochemical profile, glycemia, and T4/TSH levels. Fecal calprotectin was determined. Clinical exams were assessed before and after intermittent fasting. Inflammation markers, such as CRP and calprotectin, were significantly reduced after eight weeks of intermittent fasting. The patient reported feeling better and was seizure-free during the following months when she continued fasting intermittently. Intermittent fasting allowed for a reduction in inflammation markers.

show abstract

“…A recent study has shown that supplementation of dietary Zn(ii)-curcumin (ZnCM) can attenuate gut dysbiosis during DOX-induced cardiomyopathy in vivo [ 140 ]. Furthermore, recent investigation has indicated that intermittent fasting (IF) has the potential to modulate the composition of gut microbiota, contributing to improvements in obesity and host energy metabolism [ 141 ]. Interestingly, a recent significant study found that alternate-day fasting (ADF) can aggravate DIC through transcription factor EB (TFEB)-mediated autophagy [ 41 ].…”

Section: The Potential Interventions Of Microbiota-targeted Therapeut...mentioning

confidence: 99%

Role of gut microbiota in doxorubicin-induced cardiotoxicity: from pathogenesis to related interventions

Huang,

Li,

et al. 2024

J Transl Med

View full text Add to dashboard Cite

Doxorubicin (DOX) is a broad-spectrum and highly efficient anticancer agent, but its clinical implication is limited by lethal cardiotoxicity. Growing evidences have shown that alterations in intestinal microbial composition and function, namely dysbiosis, are closely linked to the progression of DOX-induced cardiotoxicity (DIC) through regulating the gut-microbiota-heart (GMH) axis. The role of gut microbiota and its metabolites in DIC, however, is largely unelucidated. Our review will focus on the potential mechanism between gut microbiota dysbiosis and DIC, so as to provide novel insights into the pathophysiology of DIC. Furthermore, we summarize the underlying interventions of microbial-targeted therapeutics in DIC, encompassing dietary interventions, fecal microbiota transplantation (FMT), probiotics, antibiotics, and natural phytochemicals. Given the emergence of microbial investigation in DIC, finally we aim to point out a novel direction for future research and clinical intervention of DIC, which may be helpful for the DIC patients.

show abstract

Intermittent fasting modulates the intestinal microbiota and improves obesity and host energy metabolism

Cited by 19 publications

References 49 publications

The Safety of Novel Therapies in Chronic Lymphocytic Leukemia in the Era of Intermittent Fasting: A Pharmacology-Based Review

The Safety of Novel Therapies in Chronic Lymphocytic Leukemia in the Era of Intermittent Fasting: A Pharmacology-Based Review

Intermittent Fasting and Reduction of Inflammatory Response in a Patient with Ulcerative Colitis

Role of gut microbiota in doxorubicin-induced cardiotoxicity: from pathogenesis to related interventions

Contact Info

Product

Resources

About